The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | A Phase II study of elritercept for lower-risk MDS
María Díez Campelo, MD, PhD, University of Salamanca, Salamanca, Spain, presents the updated findings from the ongoing Phase II KER050-MD-201 trial (NCT04419649) evaluating the safety, tolerability, and efficacy of elritercept in patients with lower-risk myelodysplastic syndromes (LR-MDS) and anemia. The agent has been well tolerated and demonstrated a durable clinical benefit and an improvement in quality of life (QoL) in patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria/Speaker: BMS, Novartis, Keros; Advisory Board: BMS, Novartis, Blueprint Medicines, GSK, Agios, Hemavan, Syros, Keros, Curis, Astex/Otsuka.
